Journal: Journal of Translational Medicine

Article Title: Novel insights into hypoxia-driven transcriptomic and epigenetic landscapes in grade 3 meningioma

doi: 10.1186/s12967-025-07606-9

Figure Lengend Snippet: Hypoxia-responsive gene signatures identified in grade 3 meningioma. ( A ) Significant differentially expressed genes in hypoxic versus normoxic IOMM-Lee cells; volcano plot depicting the upregulated and downregulated genes under Hypoxic versus Normoxic conditions in IOMM-Lee (Grade 3 Meningioma cell line). ( B ) Cluster heatmap of DEGs showing top 25 upregulated and downregulated genes. The color transition from blue to red indicates a change from downregulation to upregulation. ( C , D ) RT-qPCR validation of gene expression changes at 6, 24, 48 h under hypoxic conditions (0.2% O₂). (*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001). ( E , F ) Upregulation of IGFBP3 and NDRG1 at protein level under hypoxia (0.2% O₂) at 48 h

Article Snippet: IGFBP3 specific siRNA was purchased from MedChemExpress (Cat. No. HY-RS06626, pre-designed siRNA).

Techniques: Quantitative RT-PCR, Biomarker Discovery, Gene Expression

Journal: Journal of Translational Medicine

Article Title: Novel insights into hypoxia-driven transcriptomic and epigenetic landscapes in grade 3 meningioma

doi: 10.1186/s12967-025-07606-9

Figure Lengend Snippet: IGFBP3 expression positively correlates with VEGFA and regulates meningioma cell viability and migration. (A–B) Correlation of IGFBP3 and NDRG1 expression with VEGFA in meningioma patients. ( C ) RT-qPCR validation of IGFBP3 across tumor grades and recurrent vs. non-recurrent cases. (D) Confirmation of IGFBP3 downregulation at the protein level upon IGFBP3 siRNA transfection via western blotting ( n = 2) ( E ) IGFBP3 depletion reduces meningioma cell viability. ( F-G ) Wound-healing assay showing reduced migration upon IGFBP3 silencing

Article Snippet: IGFBP3 specific siRNA was purchased from MedChemExpress (Cat. No. HY-RS06626, pre-designed siRNA).

Techniques: Expressing, Migration, Quantitative RT-PCR, Biomarker Discovery, Transfection, Western Blot, Wound Healing Assay

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Clinical characteristics of samples in two cohorts

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques: Biomarker Discovery

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Level and ROC curve analysis of serum IGFBP3 for EJA. Serum IGFBP3 levels in normal controls, EJA and early-stage EJA patients in training cohort ( A ) and validation cohort ( B ) are shown in scatter plot and box plot. The lines in the box are means. The ROC curves of serum IGFBP3 to distinguish EJA and early-stage EJA patients and normal controls in training cohort ( C ) and validation cohort ( D ). The “EJA” curve (blue line) shows healthy subjects vs. all EJA subjects (early + late-stage), and the “early-stage EJA” curve (green line) shows healthy subjects vs. only the early-stage EJA subjects. EJA esophagogastric junction adenocarcinoma, ROC receiver-operating characteristics curve

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques: Biomarker Discovery

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Diagnostic results of serum IGFBP3 in EJA

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques: Diagnostic Assay, Biomarker Discovery

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Kaplan–Meier curves for serum IGFBP3 with EJA patients. Patients with low serum IGFBP3 level had short survival. EJA esophagogastric junction adenocarcinoma

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques:

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Construction and performance evaluation of the nomogram. Nomogram based on serum IGFBP3, tumor size and TNM stage to predict the 1-, 3- and 5-years OS for EJA patients. The nomogram used by adding the points determined on the point scale of each variable, the total points projected on the bottom scales match the probability of 1-, 3-, and 5-year OS of EJA patient ( A ). Time-dependent C-index of nomogram based on serum IGFBP3, tumor size and TNM stage for OS of EJA patient ( B ) and internally validated with using a bootstrap resampling method ( C ). Calibration plots showed good agreement for the survival probability at 1-, 3- and 5-year between the nomogram prediction and actual observed results ( D – F ). Decision curve analysis of serum IGFBP3, tumor size and TNM stage and nomogram. The straight black line represents the assumption that all patients die, and the horizontal line represents the assumption that no deaths happen ( G ). Clinical impact curve of nomogram. The red curve (number of high-risk individuals) indicated the number of people who were classifed as positive (high risk) by the nomogram at each threshold probability; the blue dotted curve (number of high-risk individuals with event) was the number of true positives at each threshold probability ( H ). EJA esophagogastric junction adenocarcinoma, OS overall survival

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques:

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Predictive improvement of the nomogram

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques: Significance Assay

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: Cox proportional hazards regression analysis of OS in EJA

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques: Significance Assay

Journal: Discover. Oncology

Article Title: Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

doi: 10.1007/s12672-022-00591-1

Figure Lengend Snippet: The C-index, AIC and BIC of prognostic factors and nomogram for prediction OS

Article Snippet: The IGFBP3 concentration in the serum was measured with a IGFBP3 ELISA Kit (CUSABIO, Wuhan, China).

Techniques: Significance Assay